Patent intelligence · US
US 9217024
ADDL receptor polypeptides, polynucleotides and host cells for recombinant production
ADDL receptor polypeptides, polynucleotides and host cells for recombinant production
Patent details — US 9217024
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 22, 2015
- Expiration
- Dec 17, 2035
- Applicant
- Acumen Pharmaceuticals, Inc.
- Claims
- 27
- CPC classes
- A61P, A61P25/00, A61P25/28
Quick answer
US 9217024 (ADDL receptor polypeptides, polynucleotides and host cells for recombinant production) is held by Acumen Pharmaceuticals, Inc.. Status: granted. Granted Dec 22, 2015. Expires Dec 17, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Acumen Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 27
- CPC classes
- A61P, A61P25/00, A61P25/28
More from Acumen Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 9320793
Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
granted -
US 9006283
Methods of modifying amyloid β oligomers using non-peptidic compounds
granted -
US 8962677
Methods of restoring cognitive ability using non-peptidic compounds
granted -
US 8507206
Monoclonal antibodies that target pathological assemblies of amyloid β (Abeta)
granted -
US 7964359
Compositions and methods for the enhancement of soluble amyloid beta oligomer (ADDL) uptake and clearance
granted
Frequently asked questions
What is US patent 9217024?
US 9217024 (ADDL receptor polypeptides, polynucleotides and host cells for recombinant production) is held by Acumen Pharmaceuticals, Inc.. Status: granted. Granted Dec 22, 2015. Expires Dec 17, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9217024?
Acumen Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 6 pharmaceutical patents for this assignee.
When does US 9217024 expire?
Our index shows an expiration date of Dec 17, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.